Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mesenchymal Stromal Cell Therapy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Stromal Cell Therapy overview
Stem cell therapy is under development for the treatment of acute respiratory distress syndrome, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), systemic sepsis, primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), rheumatoid Arthritis, lupus Nephritis and crohn's Disease.. It is CD362 enriched human umbilical cord-derived mesenchymal stromal cells and is administered by intravenous and intravenous drip. The stem cell therapy is regenerative medicine therapy consisting of pure and defined stromal cells isolated from human tissue.
Orbsen Therapeutics overview
Orbsen Therapeutics is a regenerative medicine company focused on developing stromal cell treatments to address some of most challenging diseases. Orbsen Therapeutics is headquartered in Galway, Ireland.
For a complete picture of Mesenchymal Stromal Cell Therapy’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
